Zydus Cadila gets final USFDA nod for Pindolol tablets
New Delhi: Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Pindolol tablets, used for the treatment of hypertension.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg, Zydus Cadila said in a BSE filing.
Pindolol belongs to a class of beta-blockers and is used to treat hypertension.
The company said it will manufacture the drug at the group's manufacturing facility at the Pharma SEZ in Ahmedabad.
The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd